CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 99 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,127 | -34.6% | 18,703 | -12.8% | 0.00% | – |
| Q2 2023 | $36,877 | -8.8% | 21,440 | -20.0% | 0.00% | – |
| Q1 2023 | $40,457 | -44.8% | 26,793 | -41.5% | 0.00% | – |
| Q4 2022 | $73,280 | +181.8% | 45,800 | +157.4% | 0.00% | – |
| Q3 2022 | $26,000 | +225.0% | 17,793 | +322.8% | 0.00% | – |
| Q2 2022 | $8,000 | +60.0% | 4,208 | +146.4% | 0.00% | – |
| Q1 2022 | $5,000 | -99.2% | 1,708 | -98.8% | 0.00% | – |
| Q4 2021 | $608,000 | -24.0% | 140,481 | -10.6% | 0.00% | – |
| Q3 2021 | $800,000 | +400.0% | 157,173 | +522.4% | 0.00% | – |
| Q2 2021 | $160,000 | -74.6% | 25,251 | -69.0% | 0.00% | – |
| Q1 2021 | $630,000 | +6900.0% | 81,460 | +5685.5% | 0.00% | – |
| Q4 2020 | $9,000 | +12.5% | 1,408 | +17.3% | 0.00% | – |
| Q3 2020 | $8,000 | -20.0% | 1,200 | 0.0% | 0.00% | – |
| Q2 2020 | $10,000 | -94.3% | 1,200 | -94.7% | 0.00% | – |
| Q1 2020 | $174,000 | -63.4% | 22,657 | -60.4% | 0.00% | – |
| Q4 2019 | $475,000 | -27.8% | 57,199 | -35.9% | 0.00% | – |
| Q3 2019 | $658,000 | +146.4% | 89,231 | +274.5% | 0.00% | – |
| Q2 2019 | $267,000 | +105.4% | 23,828 | +97.9% | 0.00% | – |
| Q1 2019 | $130,000 | -90.1% | 12,038 | -86.2% | 0.00% | -100.0% |
| Q4 2018 | $1,315,000 | +500.5% | 87,111 | +634.9% | 0.00% | – |
| Q3 2018 | $219,000 | +313.2% | 11,853 | +413.3% | 0.00% | – |
| Q2 2018 | $53,000 | -95.9% | 2,309 | -95.0% | 0.00% | -100.0% |
| Q1 2018 | $1,307,000 | +453.8% | 45,937 | +311.3% | 0.00% | – |
| Q4 2017 | $236,000 | -15.1% | 11,170 | -27.1% | 0.00% | – |
| Q3 2017 | $278,000 | +612.8% | 15,319 | +508.1% | 0.00% | – |
| Q2 2017 | $39,000 | -26.4% | 2,519 | -17.2% | 0.00% | – |
| Q1 2017 | $53,000 | +17.8% | 3,044 | -25.1% | 0.00% | – |
| Q4 2016 | $45,000 | +221.4% | 4,062 | +363.7% | 0.00% | – |
| Q3 2016 | $14,000 | +180.0% | 876 | +117.9% | 0.00% | – |
| Q1 2016 | $5,000 | -64.3% | 402 | -39.5% | 0.00% | – |
| Q4 2015 | $14,000 | – | 664 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 524,763 | $7,924,000 | 3.84% |
| Congress Park Capital LLC | 123,311 | $1,862,000 | 2.05% |
| Perceptive Advisors | 2,911,715 | $43,588,000 | 1.66% |
| RTW INVESTMENTS, LP | 908,586 | $13,720,000 | 1.28% |
| HAMILTON LANE ADVISORS LLC | 68,753 | $1,038,000 | 0.91% |
| HARBOURVEST PARTNERS LLC | 79,193 | $1,196,000 | 0.57% |
| SPHERA FUNDS MANAGEMENT LTD. | 273,151 | $4,125,000 | 0.46% |
| Exane Asset Management | 50,000 | $755,000,000 | 0.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 622,548 | $9,400,000 | 0.38% |
| Cormorant Asset Management, LP | 296,712 | $4,480,000 | 0.36% |